# Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators

> **NCT06672952** · NA · RECRUITING · sponsor: **Lindenwood University** · enrollment: 60 (estimated)

## Conditions studied

- Exercise Performance
- Exercise Recovery
- Cognitive Function
- Nitric Oxide
- Blood Flow
- Endurance Exercise

## Interventions

- **DIETARY_SUPPLEMENT:** 400 mg CITRAPEAK® (glucosyl-hesperidin) supplementation
- **DIETARY_SUPPLEMENT:** Placebo
- **DIETARY_SUPPLEMENT:** 200 mg CITRAPEAK® (glucosyl-hesperidin) supplementation

## Key facts

- **NCT ID:** NCT06672952
- **Lead sponsor:** Lindenwood University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-15
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06672952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06672952, "Dose-Response Impact of Glucosyl-Hesperidin (CitraPeak) on Exercise Performance, Blood Flow, Stress, Cognition, and Other Perceptual Indicators". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06672952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*